MML Investors Services LLC Makes New Investment in Vaxcyte, Inc. (NASDAQ:PCVX)

MML Investors Services LLC acquired a new stake in Vaxcyte, Inc. (NASDAQ:PCVX) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor acquired 2,274 shares of the company’s stock, valued at approximately $260,000.

A number of other hedge funds have also modified their holdings of the stock. China Universal Asset Management Co. Ltd. grew its position in Vaxcyte by 68.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 21,466 shares of the company’s stock valued at $2,453,000 after acquiring an additional 8,685 shares during the period. Natixis Advisors LLC boosted its stake in shares of Vaxcyte by 61.1% in the 3rd quarter. Natixis Advisors LLC now owns 22,697 shares of the company’s stock valued at $2,594,000 after purchasing an additional 8,606 shares in the last quarter. Tri Locum Partners LP bought a new stake in shares of Vaxcyte in the 2nd quarter worth about $8,559,000. Hsbc Holdings PLC acquired a new stake in shares of Vaxcyte during the 2nd quarter worth about $1,053,000. Finally, Lisanti Capital Growth LLC increased its position in shares of Vaxcyte by 68.1% during the 3rd quarter. Lisanti Capital Growth LLC now owns 32,515 shares of the company’s stock worth $3,715,000 after purchasing an additional 13,175 shares in the last quarter. 96.78% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $88.78, for a total value of $710,240.00. Following the sale, the chief financial officer now directly owns 109,491 shares in the company, valued at $9,720,610.98. This trade represents a 6.81 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Grant Pickering sold 2,366 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $103.89, for a total transaction of $245,803.74. Following the transaction, the chief executive officer now owns 137,398 shares of the company’s stock, valued at $14,274,278.22. The trade was a 1.69 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 117,830 shares of company stock worth $12,383,030 over the last ninety days. Company insiders own 3.10% of the company’s stock.

Vaxcyte Price Performance

Shares of Vaxcyte stock opened at $85.91 on Thursday. Vaxcyte, Inc. has a 1 year low of $53.83 and a 1 year high of $121.06. The company has a market capitalization of $10.71 billion, a P/E ratio of -18.68 and a beta of 0.94. The business has a 50-day moving average of $96.95 and a two-hundred day moving average of $92.58.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same quarter last year, the company earned ($0.91) EPS. On average, equities analysts anticipate that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have weighed in on PCVX. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. BTIG Research raised their price target on Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Leerink Partners upped their price target on Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a research note on Tuesday, September 3rd. Bank of America raised their price objective on shares of Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, September 4th. Finally, Mizuho upped their price objective on Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a report on Tuesday, September 10th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, Vaxcyte currently has a consensus rating of “Buy” and a consensus target price of $145.71.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.